oral MET kinase inhibitor

approved for clinical use in NSCLC

internal HTS and SBDD

Clinical Cancer Research

Merck KGaA

Chemical structure of molecule Tepotinib (Merck KGaA MET kinase inhibitor)

9.      The Merck KGaA MET kinase inhibitor, tepotinib, was approved earlier this year for METex14 positive NSCLC patients, and is administered once-daily in contrast to capmatinib, which was approved in 2020. Both…

get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: